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Abstract 
Since outbreaks in 2003, avian influenza has received a considerable amount of funding and become a 
controversial science policy issue in various respects. Like in many so-called “grand challenges”, a variety 
of perspectives have emerged over how to “tackle” avian influenza and public voices have expressed 
concern over how research funds are being allocated. In this article we inquire into the priorities of avian 
influenza research. We use qualitative and quantitative data to examine the relations between societal 
demands for public science and the existing “research landscape”. Interviews of a cross-section of 
stakeholders revealed a diversity of perspectives on existing research and its desired outcomes, and a 
generalized difficulty to explicitly connect the two. We also observed a lack of a common understanding 
of priorities for conducting and applying research. Rather than well-defined research agendas, we found 
that most public avian influenza research is shaped by three institutional contexts: pharmaceutical 
industry priorities, publishing and public research funding pressures, and the mandates of international 
and national science-based policy or public health organizations. Our results are significant for informing 
not only resource allocation issues, but also a broad perspective of research governance that explicitly 
takes into account underlying incentive structures when defining priorities. 
1. Introduction 
A central question in science policy is how the research system can be mobilized to help tackle grand 
societal challenges.  In particular, research can be mobilized as a part of a broader response to what are 
broadly viewed as security threats such as climate change, malaria or antibiotic resistance. These 
challenges involve a range of stakeholders with different understandings and expectations as to what the 
risk is, what specific solutions should be sought, what role science and technology should play and how 
research should be configured to address the challenge.  
The analysis of these multi-faceted, socio-technical issues is beset by the uncertainty and ambiguity of the 
problem framings, the difficulty in reconciling the demands (i.e. the outcomes expected from research by 
policymakers and other stakeholders) with the supply (i.e. the actual and potential outputs of research), 
and the complexity of linking the relevant areas of knowledge and actors (Sarewitz & Pielke, 2007, Wallace 
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and Rafols, 2015). This is particularly challenging in the public sector, which is beholden not only by 
financial pressures but also a wide and divergent range of social forces and lobby groups.  
The problem of managing research and attributing resources according to societal needs has been so far 
focused on prioritisation between competing problems. This has been mostly explored in the area of 
public health. For example, scholarship has explored whether or not the funding for different diseases is 
commensurate with their burden (Agarwal & Searls, 2009, pp. 867–869; Evans, Shim, & Ioannidis, 2014). 
However, the literature has yet to explore how research governance has an effect on research 
prioritisation for (or within) a given challenge – which affects not only how resources are allocated and 
but also what type of research is conducted (e.g. epidemiology vs. molecular biology).  
Public scrutiny over research prioritisation is about demonstrating “value for money”, focusing on the 
“right” priorities, as well as more generally being responsive to public concern over how research is 
undertaken and used. In this vein, scholars and practitioners have called for more inclusive processes of 
deliberation (Stirling, 2007b) and for more consideration to debates on research happening both within 
the scientific community and broader public spheres. We can thus view the research and the research 
problem itself as being co-constructed by as a scientific and political object through both scientific and 
political institutions (see, for example, Jasanoff, 2004).  
One cannot simply reduce the prioritisation problem to that of funding allocation, since conducting  and 
applying research are processes that depend on various institutional contexts and pressures. These 
institutions, as structures that influence the behaviour of researchers, policymakers and users of scientific 
information, play a key role in priority setting, and determine to a large extent the outputs and societal 
impacts of research produced (Heinze, Shapira, Rogers, & Senker, 2009; Laudel & Gläser, 2014). Indeed, 
science and technology policies aim not only to set funding and priorities, but to have an impact on a 
broader range of governance options that affect various stages of the research process (Foray, Mowery, 
& Nelson, 2012).  
In this study we broadly follow Gläser’s conceptual framework on the governance of research contents 
(Gläser, 2012; Laudel and Gläser, 2014): individual researchers “freely” choose research topics (as 
illustrated by laboratory studies), but their choices are influenced by institutional contexts. The key 
question then is to understand the links between research governance (as felt by individual researchers 
via a variety of institutional pressures), research contents and the social outcomes of such research. 
In a recent paper, we explored how a “research portfolio” framing of societal challenges might help in 
fostering a better alignment between science "supply” and societal “demands” (Wallace and Rafols, 
2015).  In this paper, we empirically investigate how public research resources are mobilised to tackle a 
grand societal challenge for the case study of avian influenza, and we also study the institutions that 
govern (in a broad sense) research and shape outcomes. A contribution of this paper is to be one of the 
few studies so far tentatively linking qualitative investigation on research contents with macro-scale 
science policy analysis (Laudel and Gläser, 2014).  It also intends to bridge the gap between a more social 
constructivist scholarship that links perceptions of risk (for example, of a pandemic) with a research 
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agenda (Jasanoff, 2004; Stirling, 2007b), and a research management or science and innovation policy 
perspective that seeks practical solutions to administering such “grand societal challenges”.  
Avian influenza research is found to be a highly contested topic. We first show that there is a widespread 
difficulty to link specific research avenues with societal outcomes. This is compounded by stakeholders’ 
diverging, value-laden views on both aspects. The lack of a shared understanding is a major obstacle to 
prioritisation. Rather than strategic research agendas, we find that current institutional dynamics 
mediates priority setting: pressures arising from the pharmaceutical sector, or associated with publication 
and obtaining grants, and, to a lesser degree, mandate-driven (governmental or intergovernmental) 
public organizations are shown to shape what types of avian influenza research is undertaken.   
The article is organised as follows. In section 2 we introduce a mixed methods approach which combines 
interviews and scientometric mapping. In Section 3, we present avian influenza research as the response 
to a “shock” to the research system. This results not only in an influx of resources, but also in a field that 
is multi-faceted, multi-stakeholder and associated with various sociotechnical controversies. In Section 4, 
we explore stakeholder perspectives on avian influenza research covering the following aspects: 1) views 
of societal demands, i.e., desirable outcomes of avian influenza research; 2) descriptions of the science 
supply, i.e., the research landscape; and 3) the main institutional contexts that have an effect in the 
shaping of research contents. Our qualitative interview data are supported by a quantitative analysis of 
the research landscape and main science policy issues through the mapping of scholarly publications and 
funding. Section 5 discusses the insights. 
2. Methodology 
Given that it is very problematic to generate or access reliable information on research supply and societal 
demands for a challenge such as avian flu, we have opted for a mixed methods approach. On the one 
hand, we relied on funding and publication data to describe research supply. On the other hand, we 
interviewed informed stakeholders, i.e. scientific experts and policy makers. Informed stakeholders were 
interviewed in order to a) characterise the landscape of research options, b) link research options to 
societal outcomes of avian influenza research and make value judgments about research priorities and 
policy objectives. The approach assumes that there are some common understandings of the risks of avian 
influenza and the research options to mitigate it.  
2.1 Semi-structured interviews 
A series of semi-structured interviews were conducted to gather a wide variety of perspectives from 
stakeholders. For this purpose, fourteen interviewees were asked to describe avian influenza research in 
terms of trends and structure of the field, as well as its outcomes and institutional drivers. The 
interviewees selected were at relatively senior positions within organizations that were involved in avian 
influenza research as producers, users or otherwise influential actors regarding the direction of public 
research. The selection aimed to have candidates from various sectors and countries across Europe. As a 
starting point for seeking out patterns and characterizing responses, interviewees were classified based 
on their degree of technical knowledge of any area(s) scientific research related to avian influenza, as well 
as their degree of policy knowledge or influence, based on their organizational affiliations (see Figure 1). 
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Face-to-face interviews took place between February and June of 2014, in the UK, the Netherlands, 
Belgium, Luxembourg, Spain and Italy, with each interview lasting between one and two and a half hours. 
 
Figure 1. Schematic representation of the distribution of main stakeholders interviewed (arbitrarily assigned a number of 1 
to 14) according to policy and technical expertise 
Participants were asked about their views on various aspects of avian influenza research: what types of 
research options could be considered, which were prioritised, what obstacles or challenges they faced. 
We did not intend to make generalizations or statistically significant conclusions about their perspectives 
on avian influenza research. Rather, the interviews were designed to understand what types of views exist 
about this field of study and to suggest connections between the type of research conducted and its 
outcomes. We focused on extracting the context surrounding the account provided by interviewees, on 
seeking out instances of divergence and consensus among participants, as well as on institutional factors 
deemed important by researchers (Benner & Sandström, 2000; Goldfarb, 2008; Heinze et al., 2009; Laudel 
& Gläser, 2014). 
Through the interviews we obtained views on how the research contents (supply) and outcomes 
(demands) are related. To do so, we appraised participants’ perspectives of the different desirable 
outcomes and the different research options for achieving them. We also asked participants to discuss 
institutional factors that affect the interplay between content and outcomes. This approach allowed us to 
capture narratives and frames associated with different types of avian influenza research, as well as the 
relationship between institutional drivers and research options, as perceived by participants. 
2.2 Quantitative data mined from funding and publications 
Our analysis was supported by quantitative data on publication on avian influenza over the past 10 years. 
Delineating a research topic with keywords is difficult and controversial. Our data was obtained by first 
obtaining the list of all publications pertaining to avian influenza through the Medical Subject Headings 
(MeSH) of the PubMed system (Rotolo & Leydesdorff, 2015). Specifically, under the parent heading of 
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Influenza A as an organism, we selected specific strains (e.g., H5N1, H7N9), combined with articles tagged 
as “Influenza in Birds” under the separate parent heading of “Orthomyxoviridae infections”. This corpus 
of articles allowed us to study the research landscape associated with a given set of diseases, as well as 
to compare it with the research associated more broadly with Influenza A (which includes “swine flu”, as 
well as seasonal influenza strains).  
In order to illustrate the diversity and balance of topics and approaches associated with avian influenza, 
we focused on “mapping” the research landscape as a cognitive space defined by methodologies, theories, 
disciplinary traditions and different objects of research. While this can be done through several methods 
such co-citation or bibliometric coupling analyses, we found that maps generated through the network of 
co-occurrence of terms within the abstracts using the VOSviewer software package, provided a fast and 
easy-to-use interface so as to identify clusters within the landscape (van Eck & Waltman, 2010; Waltman, 
Eck, & Noyons, 2009).  
With maps or “basemaps” formed by all avian influenza publications (n=3,700) between 2004 and 2013, 
we overlaid subsets of this dataset in order to visualize only the research associated with specific 
disciplines (through the classification of journals), research organizations (through the addresses of 
authors) or funding organizations (through the acknowledgements of funding captured in Web of 
Science). Specifically, we fixed the locations of the terms found in the basemap, while adjusting the weight 
assigned to each term based on its occurrence of relative occurrence within a subset. Various settings 
were used to represent these overlays in order to visualize changes with respect to the basemap. In 
general, one needs to take care that setting the threshold of most “relevant” terms (which exclude the 
common terms such as “influenza”) and the minimum number of occurrences of a given term, does not 
change the overall shape of the map. In other words, maps have to be tested for robustness for various 
settings so as to ascertain that the perspective provided is not an artefact of the choice of parameters.    
3. Background: avian influenza as a case study 
In this section we provide an overview of the avian influenza problem from a science policy perspective. 
We paint a picture of a research area that underwent a period of tremendous growth in funding 
worldwide, though dominated by a few major funding and performing research institutions. Over the last 
10 years, avian influenza is associated with debates on different types of risk and uncertainty, and that 
are influential inside and outside the scientific community. This implies a need to consider avian influenza 
research not only in the broader context of influenza overall, but also in terms of a wide range of policy 
and stakeholder interests. 
3.1 Global research and policy context of influenza  
Institutional responses to disease and paths to intervention legitimized by scientific knowledge are crafted 
by perspectives of actors working in the area (Kreimer & Zabala, 2007). Influenza is simultaneously a 
scientific, a political and a social object (Quinn, 2008). Historically, influenza has remained elusive to 
researchers, in large part because of the ability of the virus to mutate, to have varying levels of virulence 
to spread both through animals and humans. Similarly, preparedness measures or responses to epidemics 
do not tend to be one-dimensional. A “one size fits all” or purely technocratic response fails to recognize 
the variety of local conditions and concerns. Also, preparing for a pandemic should recognize the high 
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levels of uncertainty associated with influenza and therefore, favour a pluralistic approach (Forster, 2012). 
Being a global problem, the overall response has been heavily influenced by three international 
institutions with a focus on human health (the World Health Organization), agriculture and livestock (the 
Food and Agriculture Organization) and animal health (the International Organization for Animal Health 
or OIE), under the aegis of a “coevolution” of science and policy (Chien, 2013).  
Previous work by Ian Scoones has revealed that the three distinct dominant narratives of control are 
focused on veterinary medicine, public health and pandemic preparedness (Scoones, 2010 Chapter 1). 
The existence of contending narratives  is a source of significant tension in the development of policy. This 
tension has led to the construction of new worldviews (and programs) such as “One Health”, which sought 
to integrate the animal and human dimensions of influenza. Various framings of risk have arisen due to 
so-called “pandemic threats” or “emerging diseases”, highlighting differences between global 
preparedness and control measures at the local level. Often, framings of the issue in response to a 
perceived risk can be characterized by assigning blame to or stigmatizing other (usually less powerful) 
groups (Abeysinghe & White, 2011; Barrett & Brown, 2008; Global Health Watch, 2011, pp. 146–153; King, 
2002). 
3.2 Setting the stage: trends in incidence, research funding and public 
debate 
While all Influenza A strains can in theory be carried by birds, avian influenza usually refers to specific 
strains which are dominated by birds (as opposed to swine, for example). Furthermore, the bulk of 
research over the past ten years has tended to focus on highly-pathogenic strains of avian influenza, 
especially those which may be susceptible to cross-species transmission. In many arenas of policy and 
research, the term “avian influenza” itself is still closely linked to a perceived risk of the specific H5N1 
strain (responsible for most outbreaks since 2003), although the recent emergence of new highly-
pathogenic strains such as H7N9 has also become a serious concern. Overall, however, there is 
considerable overlap, both from a policy and research perspective, with other types of influenza. 
Table 1 summarizes the number of H5N1 cases and deaths reported since 2003, primarily in Southeast 
Asia, but also in other countries such as Turkey and Egypt. Another avian influenza strain, H7N9, has 
infected an estimated 453 people, killing 175 in 2013-14.1 To provide some comparison, the 2009-2010 
swine influenza pandemic (H1N1) killed at least 18,500 people, based on laboratory-confirmed tests, 
though the estimate of total deaths is much higher (up to 201,200) (Dawood et al., 2012). While 
developing countries have advanced, to varying degrees, approaches to tackle the outbreaks within their 
borders (Scoones, 2010, Chapters 3-6), developed countries have been primarily concerned with dangers 
of a global pandemic (Abeysinghe & White, 2011). The swine influenza pandemic of 2009 thus served in 
part to confirm these fears, while shifting the focus to other strains of influenza such as H1N1. 
                                                          
1 October 2, 2014 WHO risk assessment from 
http://www.who.int/influenza/human_animal_interface/influenza_h7n9/Risk_Assessment/en/  
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Table 1: Number of deaths and reported cases of H5N1 worldwide between 2003 and 20132 
Year H5N1 – reported cases H5N1 – deaths 
2003 4 4 
2004 46 32 
2005 98 43 
2006 115 79 
2007 88 58 
2008 44 33 
2009 73 32 
2010 48 24 
2011 62 34 
2012 32 20 
2013 39 25 
 
Figure 2 shows the funding profile for avian influenza as a “response” to this crisis, both in absolute dollars 
and as a proportion of total influenza funding. Figure 3 shows the number of publications associated with 
Influenza A and avian influenza. The data from the US point a rapid increase in funds, followed by a recent 
decline, which confirms recent reports from the UK that this was a period in which influenza research in 
general grew significantly, especially considering its “burden” relative to other diseases (Head et al., 2014). 
Furthermore, while avian influenza dominated the influenza A research landscape prior to 2009, the 
emergence of the swine influenza pandemic shifted research priorities significantly. Thus, beyond the 
increases in inputs and outputs, these patterns point to the need to understand how research systems—
in particular, dominant institutions—responded to a large “shock” (and influx of funding) in 2003-04, 
followed by another one in 2009. 
                                                          
2 July 27, 2014 data taken from the WHO at 
http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/ 
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Figure 2. Vertical bars: NIH funding (in millions of dollars) for avian influenza, by fiscal year. Dotted line: avian funding 
expressed as a fraction of total spending on influenza, including H1N1.3 
                                                          
3 Data downloaded using NIH RePORTER tool (http://report.nih.gov/), June 2014, using keywords pertaining to 
influenza overall and strains typically associated with “avian influenza” (H5N1, H7N9). Both project and sub-project 
funding is included. 
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Figure 3. Number of papers published on two major strains of Influenza A. H5N1 is the strain most commonly associated with 
avian influenza. 
There are a variety of science policy debates when there is a rapid increase in research on a contentious, 
high-profile issue. These debates can be in part captured through discussions in prominent scientific 
journals (Waaijer, van Bochove, & van Eck, 2011). We performed a search for editorials related to avian 
influenza4 in Science, Nature, The Lancet, British Medical Journal, New England Journal of Medicine and 
the Proceedings of the National Academies of Science and apply an ad hoc classification (acknowledging 
significant overlap) of the 84 editorials found. “Vaccine and treatment” refers to the pharmaceutical 
methods to mitigating risk (in particular, the debate over their effectiveness or equitable access); 
“characterization” refers to debates over the nature and origins of the disease; “dual-use research” refers 
to the risk associated with gain-of-function experiments for bioterrorism or inadvertent escape of the 
virus; “control” refers to debates over the most effective strategies for mitigating risk (on a national or 
global scale); and “pandemic risk” refers to the debate over estimating the risk of a global pandemic.  
Figure 4 summarizes the evolution of these topics, indicating the waxing and waning of various debates. 
Initial debates focused on defining risk, while later debates tended to focus on dangers of “advanced” 
research (2012), or characterization and control of new strains (2012-2013). Our cursory examination of 
editorials points to a variety of sociotechnical framings of the research itself, which go beyond a 
technocratic approach to risk management (Slovic, 1993). While some of these themes are focused on the 
                                                          
4 Here, we searched for the terms “avian flu”, “avian influenza”, “bird flu”, H5N1 and H7N9 in these journals and 
restrict ourselves to the “editorial material” category of articles in Web of Knowledge. 
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uses of research (e.g., vaccines and treatment), others pertain more to the content of research (e.g., the 
characterization or avian influenza) and a significant number of debates speak to both of these elements. 
The controversies point to an engagement of policymakers, researchers and the public in defining (or 
seeking to define) the research agenda, especially as it pertains to risk mitigation. Indeed, our interviews 
revealed strong opinions among almost all stakeholders that “research funds are not addressing the right 
priorities”. The following sections of this paper aims not to assess whether this is empirically “true”, but 
to characterize such a disconnect or, more generally, the difficulties in linking research with outcomes. 
 
Figure 4: Number of editorials regarding avian influenza in leading scientific journals, manually assigned to five different 
categories. 
4. Results: Perceptions of societal demands, research supply and the 
mediating role of institutions  
4.1 Demand: diverging views on desirable societal outcomes 
This section explores the challenges in linking research and outcomes by focusing on the latter. We first 
begin by describing the diversity of stakeholders’ perceptions of how the risk of an avian influenza 
pandemic can be mitigated by research. We then explore the challenges associated with articulating 
specific pathways to outcomes.  
4.1.1 Narratives of risk 
Risk framings play a dominant role in how the overall context of avian influenza control, including 
research, is perceived. These perspectives speak primarily to the way risk is viewed within a given 
institutional context (Kasperson et al., 1988). Figure 5 highlights the existence of diverse frames, 
heterogeneous perspectives and lack of consensus regarding risk. These differences exist even within the 
same type of stakeholders. We can summarize perceptions of risk in three different ways. The first 
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concerns the level of uncertainty associated with a future epidemic, e.g. whether one believes that a 
pandemic similar to that of 1918 is likely to occur or not. The second deals with a normative vision of risk 
assessment processes and whether the pandemic “threat” can be best addressed through formal, 
standardized mechanisms (generally by larger organizations) or through a more subjective, informal 
procedure (generally in smaller field or lab-based settings). For example: 
The zoonotic risk. Not in a formal way. […] In a, sort of, “God, this looks bloody dangerous,” 
or “This one looks about the same as,” such and such. […] It’s a gamble. But, you know, 
what you’re trying to do is you’ve got to have - you can’t do it by sticking things into 
computer programs. It’s sort of like a general feel for things that - I think it’s a general feel 
(government researcher). 
 
Figure 5. A schematic representation of the three axis according to which we describe perceptions of risk and risk mitigation. 
The numbers refer to individual interviewed stakeholders (see Figure 1). Note that many stakeholders did not express a specific 
preference along some of the axes, hence not all interviewees are represented. No strong correlation was found with 
interviewees’ expertise, as represented in the two axes of Figure 1. 
The situation is further complicated by the fact that many recognize the possibility of adverse outcomes 
of research. In the case of avian influenza, the most well-known is dual-use research, commonly 
associated with “gain-of-function” experiments, whereby viruses undergo mutations in a laboratory 
setting (for example, Herfst et al., 2012), leading to, some argue, a safety risk for the general public. Since 
2011, this has been an object of intense technical, ethical and policy debate, with significant implications 
for the governance of research (Edwards, Revill, & Bezuidenhout, 2014; Suk, Bartels, Broberg, Struelens, 
& Ozin, 2014). Others hinted at control measures arising from flu research that might have an 
unacceptably adverse effect on livelihoods. These findings point to the need to recognize a broad range 
of uncertainties associated with research itself.  
The narratives put forth by stakeholders point to a plurality of fundamentally different views on risk and 
its management or mitigation. Beyond the well-documented conceptual and institutional gaps between 
scientists and policymakers, or between how the public and “experts” perceive risk, our results highlight 
that there are diverging fundamental framings of risk, which are heavily influenced by an individual’s 
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background and institutional context. How a researcher views the main challenges associated with avian 
influenza in turn has an impact on perceptions of specific pathways to solutions. 
4.1.2 Pathways from research to solutions 
Next we characterize the normative views of stakeholders as preferring a “top-down” or “bottom-up” 
approach for risk mitigation strategies (see Figure 5). In general, top-down approaches speak to 
technological solutions which are centrally deployed (internationally or by country), while bottom-up 
solutions are more associated with solutions which take into account the local socio-economic conditions. 
The analysis of the interviews suggests that those with high levels of technical knowledge tend to view 
“bottom-up” expertise as a good means to gauge risk and inform public health policy. However, the 
frames favoured by stakeholders are not primarily based on the level of technical knowledge or on the 
level of involvement with policy.  
Another critical issue for stakeholders is where the science policy decisions are made or, alternately, 
where the onus lies for decision-making regarding the allocation of resources for research. In comparison 
to other public health issues, or even other infectious diseases (e.g., HIV, malaria), influenza research 
funding is not seen as an area where a wide range of stakeholders can or should participate in decision-
making. This lack of engagement in science policy results in more influence over research by incumbent 
assumptions and institutional norms. Specifically, scientists or research managers view the decisions as 
“purely political”, while those involved in health policy view the decisions as “purely technical”. For 
example, when discussing vaccines:  
If we would have vaccines, which are prepared and tested, then we would be in a better 
situation for protection, just in case. But that's a political and a governmental decision. It's 
not a technical purpose (researcher) 
[vaccine development efforts] are moving a bit too slow, which might be related to a number 
of factors including technical and scientific factors, but maybe related in the fact that there 
are not enough funds to allow such enterprises and such ideas to move forward. 
(policymaker). 
Stakeholders both within and beyond the research community found it difficult, and sometimes 
impossible, to articulate specific pathways from research agendas to solutions. While there is general 
agreement on the need to “tackle” avian influenza or to “guard against” future epidemics, any steps 
towards these general outcomes were usually not framed via a pathways fostered by specific research 
goals. While many shared a taxonomy of possible mitigation strategies as either antiviral drugs, vaccines 
or non-pharmaceutical interventions, such distinctions are subjective, not unanimous and do not lead to 
the articulation of specific priorities (Ferguson et al., 2006). This includes, for example, whether we should 
focus on improving existing influenza vaccines or on developing new ones, and how this related to 
problems of access to, as well as distribution and production of vaccines (Fidler, 2010; Friede et al., 2011). 
In the case of non-technological pathways (e.g., focusing on primary care, socioeconomics or national 
surveillance) for addressing avian influenza, the gap between research and identifiable outcomes often 
appears even wider.  
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4.2 Supply: redefining the avian influenza research landscape 
A second difficulty in setting priorities is associated with a lack of common understanding of the research 
options. Interviews revealed an unexpected disagreement regarding possible research areas of themes 
associated with avian influenza. As we explain in this section, not only is the division of research into 
cognitive categories (distinct bodies of knowledge) ambiguous, but there are inherently divergent 
worldviews as to what constitute “promising” areas of research.  
4.2.1 Characterizing distinct research options 
Even though disciplinary norms and perspectives are well-entrenched in the scientific communities and 
thus remain dominant (Becher & Trowler, 2001; Bourdieu, 1976), many societal challenges are 
increasingly viewed as requiring multi- or inter-disciplinary approaches. This means that the knowledge 
base for societal challenges can be expected to draw upon various disciplinary areas. Therefore, the 
integration of a broad spectrum of cognitive perspectives is often cited as a desirable to tackle “complex 
problems” such as avian influenza (Rosenfield, 1992). Stakeholders interviewed generally agreed that 
there is a need for diverse research avenues that transcend traditional disciplinary divisions. 
To illustrate this diversity, we develop a semantic map of avian influenza research (Figure 6) based on 
terms found in abstracts of scientific articles between 2004 and 2013 using the VOSViewer software. The 
vocabulary provides us with a sense of what type of methods and objects dominate a given area of 
research (see caption of Figure 6). Interestingly, the clusters cannot be easily characterized with 
disciplinary labels. In particular, our interviews called into question simple interpretations of terms such 
as “virology”, “immunology” and “epidemiology”, which are commonly associated with specific types of 
research. Both the identification of the main fields and the language used to describe these fields varied 
widely among participants.  
As seen in Figure 6 below, the boundaries between different conventional disciplinary fields are fluid, in 
part because research objects and methodologies are not specific to a single discipline. More importantly, 
certain areas of research were found to be associated with extremely different types of outcomes. For 
example, some viewed animal research as primarily focused on understanding zoonosis, while others 
associated it mainly with control measures. Similarly, some associated epidemiological modelling with 
means for understanding the disease at early stages, while others viewed it as a source of policy 
recommendations for controlling outbreaks.  
Furthermore, we observed that seemingly “objective” labels of research areas often came with judgments 
regarding the utility or the rigour associated with them. For example, that which is closely associated with 
public health or tracking epidemics was criticized by some as “soft”, more “routine” or lacking analytical 
rigour, whereas research associated with the virus or immune response was described by others as 
“detached” from the main problems or as “too expensive” for what it yields. As such, some public research 
in a given area such as immunology was sometimes described as either over-funded in relation to the 
insights gained, while other research areas such as animal-based epidemiology were sometimes seen as 
under-funded. Modelling in virology, as in epidemiology, for example, was an area of particular 
contention, as described by a scientist working primarily in a policy arena: 
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There's a lot of research going on in modeling. You know, modeling diseases? But I always 
put some question marks. It's often difficult to model reality. There are too many 
unknowns and uncertainties. The danger is if you present a policymaker with a nice model 
with curves moving round and things, they tend to kind of adhere to it like, “Oh, great. 
This is kind of a solution for me.”  
Participants did not view individual research areas as separate alternative options for tackling influenza 
research, preferring to consider various combinations of disparate fields of research. Indeed, research 
portfolios of programmes or organisations are thus characterized by varying proportions of resources 
being devoted to different types of research.   
 
Figure 6. Map of the research landscape of avian influenza. The colours denote various clusters found through VOSViewer’s 
clustering algorithm, while the proximity denotes the level of co-occurrence of the terms. Here, only terms among the 60% 
most “relevant” (i.e., allowing to distinguish between clusters) and appearing at least 6 times are kept (see details in Methods 
section). Based on the terms alone, the top left corresponds to work related to vaccine development and understanding the 
immune system; the bottom left focuses on the virological processes and on drug development; the top right is related to 
epidemiology and pandemic preparedness; the bottom right on characterizing the virus origins and spread; and clusters in the 
middle are related to detection and diagnosis. An interactive version of the map can be found here [hyperlink to be added]. 
 
 15 
 
Figure 7. "Heat map" overlay of Figure 6 highlighting the concentration of different terms (yellow and red indicate higher 
frequency). It shows the prevalence of terms within the areas associated with specific Web of Knowledge subject categories, 
as defined by a set of journals. Clockwise, from the top left: “Pharmacology and Pharmacy”, “Public, environmental and 
occupational health” / “Health care sciences and services”, “Virology” and “Veterinary medicine”. The size of circles represents 
the absolute frequency of occurrence of terms in abstracts found in these subject categories. The colour scale (blue to red) 
indicates the relative occurrence of these terms, compared with the basemap, thus highlighting terms that are very specific to 
a given subject category. 
Perspectives on research “worldviews” 
We focus here on overall views of the research landscape, not just its constituent parts. Each participant 
presented their own distinct view of it. Those with greater technical knowledge provided a more detailed 
view, though often of a more limited scope, than those who are more associated with the policy side of 
avian influenza. Specifically, whether heavily involved in the research enterprise or viewing it from a users’ 
perspective, stakeholders usually described avian influenza research overall in terms of two (sometimes 
three) basic, but diverging, approaches. Often such dichotomies contain implicit or explicit judgments (i.e., 
one approach is seen as “more desirable” than the other). 
Participants generally divided the overall research landscape in one of four different ways: 1) basic vs. 
applied research; 2) laboratory vs. field research; 3) animal vs. human-oriented research; and 4) 
laboratory vs. clinical research. Indeed, if we examine Figure 6 in closer detail, the map can be divided in 
two parts along any of these lines. Indeed, Figure 7 illustrates these various divisions, using Web of Science 
subject categories, to show how topics or disciplines – in this example, public health, pharmacology, 
veterinary science and virology – define various polarized landscapes with “blurry” boundaries. Rarely was 
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a simple of division of “basic” vs. “applied” research invoked by stakeholders, despite the fact that many 
science institutions (including funders) still rely on this dichotomy (Calvert, 2006).  
These multiple “polarities” preclude the existence of any universal means of decomposing the research 
landscape into a set of “value-free” categories. Indeed, the research gaps that stakeholders identified in 
research are directly related to how they viewed different fields in terms of being more related or similar 
to each other, or how they saw the scientific community separated in two camps at the national or 
international level. Coupled with the diverging views on risk mitigation as research outcomes as 
impediments to research prioritisation, the question is then what institutional factors drive the research 
agenda and how.  
4.3 Incentives and institutions that drive the research agenda 
While stakeholders perceived the landscape and outcomes of research differently, they generally agreed 
in finding that, despite significant investments in the past decade, public research is to varying degrees 
“misaligned” with public health priorities for avian influenza. Participants also agreed that “good” 
research needed to be able to quickly adapt to avian influenza epidemics and that there are significant 
benefits to pursuing different approaches and increasing linkages between disparate areas of research 
(on all scales). Most importantly, participants agreed that various institutions play a role in preventing 
research from most “effectively” contributing to outcomes, or that these institutions could somehow “do 
a better job” (e.g., through new coordination measures) at promoting higher quality and more useful 
research in this area. Thus, achieving “better” alignment was seen not just about allocating funding but 
about improving the management, performance and use research on avian influenza.  
Therefore, in this section we explore how dominant institutions associated with the public research 
system can shape research agendas that foster or hinder alignment between “supply” and “demand”. In 
particular, three categories of pressures were identified by the narratives and normative opinions of 
stakeholders: financial incentives from the private sector, the academic reward system (including both 
funding and publishing), and explicit missions of national or international science-based organizations. 
Each interviewee’s perception of the (negative) influence of these pressures was ranked by our analysis 
as low, medium, high or not addressed (see Table 2), and associated either with research in general or 
with specific areas such as epidemiology or vaccine development. The following sections analyze this data 
and explore the contexts for these statements.  
Table 2: Number of interviewees expressing various levels of influence from categories of institutions on research. Numbers 
in parentheses indicate subset relating only to a specific area of research (e.g., vaccine development) rather than the entire 
landscape. There is no strong correlation between the views on institutions and the nature of the stakeholders or their 
respective organizations (Figure 1). 
Institution High influence 
Medium 
influence 
Low influence Not specified 
Pharmaceutical industry 6 (3) 4 3 1 
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Academic 
reward 
system 
Scholarly 
publishing 
6 (2) 3 1 4 
Funding 
incentives 
4 (3) 4 (1) 2 4 
Organisational missions 5 4 0 5 
 
4.3.1 Financial incentives and private sector influence 
The private sector, primarily through the development of vaccines and antiviral drugs, plays a key role in 
the avian influenza research landscape. Many participants viewed the pharmaceutical industries as driving 
innovation and as the main pathway to mitigating the risk of a pandemic outbreak.  They cited the fact 
that the larger financial investments from the private sector have a strong effect on how public research 
is undertaken, beyond bringing to market pharmaceutical products. For example, there are strong 
incentives engage in public-private partnerships or to supplement public with private funding, across a 
range of areas of influenza funding. This is manifest in how research policies (e.g., calls for proposals) are 
set by public entities, for example.  
Almost half of participants felt there is a strong (often seen as negative) influence from the private sector 
on public research. This view does not appear to be correlated with technical or policy “expertise”, but 
rather with an interviewee’s values or the stated missions of their respective organizations. Many 
participants also felt that the focus of the pharmaceutical industry, with a need to ensure good financial 
returns, is too narrow and that this affects the breadth of areas considered by public researchers. For 
example, some interviewees questioned the industry focus on antivirals, since one-time vaccines usually 
have the potential to generate less revenue than antivirals in the case of an epidemic, but they may in 
fact have a stronger impact on mortality and infection (Ferguson et al., 2006).  
Figure 8 illustrates where the focus of private sector support lies in the overall research landscape. 
Although insights are limited, it shows the focus on vaccines and antivirals mentioned, and a potential 
lack of diversity when considering the multitude of perspectives on risk and risk mitigation. This focus is 
likely to support a “lock-in” of solutions based on revenue-generating pharmaceuticals, precluding a 
diversity of options implicit in the broader sociotechnical debates (Stirling, 2007a). Specifically, this tends 
to inhibit focused efforts non-pharmaceutical interventions or vaccine-based pathways less valuable from 
a market perspective. One researcher operating in the policy arena summarized the situation as follows: 
Now, very few studies, by the way, are being done in the last 20 years to look at trying to 
answer that question [what causes acute respiratory illnesses]. And this will not surprise 
you because there is very little money in these studies because they might turn up answers 
that you do not want. 
Overall, real or perceived influence from the pharmaceutical industry as a key institution in avian influenza 
research has increased tensions within the community of researchers and policymakers (especially 
regulators). It has had an indirect impact on public science through the prospect of real or perceived 
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conflicts of interest faced by researchers in such a highly politicized field, be it due to these conflicts 
affecting the conduct of public science or due to the barriers against them which prevent effective inter-
sectoral collaborations and access to private sector funding (Gulbrandsen & Smeby, 2005). The recent 
controversy over the effectiveness of the antiviral Tamiflu and the availability of data from clinical trials 
has further exacerbated tensions between some researchers (Payne, 2012)5. Overall, the narrative of 
negative influence of the pharmaceutical industry on public research is relatively pervasive, though the 
mechanisms of this influence are rarely articulated in a specific manner. Furthermore, its influence over 
the research landscape extends not only to the pharmaceutical vs. non-pharmaceutical approaches, but 
also to choices of different pharmaceutical pathways to mitigate the risk of a pandemic. 
                                                          
5 For more details on the correspondence between various parties, see: http://www.bmj.com/tamiflu/roche. 
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Figure 8. Top: Entire avian influenza research landscape (2009-13). The period is selected based on the availability of funding 
acknowledgment data from Web of Knowledge. Groupings similar to the 2004-13 case presented in Figure 6 are observed 
(clockwise, from top left, we find clusters related to vaccine development, epidemiology, veterinary science and virology). 
Bottom: overlay restricting terms to those appearing in articles acknowledging funding from the four most prevalent 
pharmaceutical companies: GlaxoSmithKline, Hoffmann - La Roche, Novartis and Sanofi Pasteur. 
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4.3.2 The academic reward system: publishing and funding 
Most participants believed that decisions regarding publication of results and regarding the allocation of 
funding played an important role in shaping avian influenza research. Grants and publications are the two 
main “currencies” of university research and how they are structured has a well-documented impact on 
the research enterprise itself (Butler, 2003). Most participants negatively viewed these pressures, since 
they lead to certain fields of research being favoured over others in terms of funding and reputation. We 
separated the reward mechanisms into two systems: the public funding system and the publishing system.  
For scientists, obtaining external research funding is not only a means for acquiring research resources, 
but also a means to gain reputation that is part of the performance assessment, even though it is not 
necessarily a good gauge of quality (Laudel, 2005). A recent (perceived) drop in funding for avian influenza 
(see Figure 2) was raised by several interviewees as having exacerbated the competition for resources. 
Some participants explained that funding schemes favoured fields such as virology and immunology that 
are perceived as more prestigious by policymakers and senior managers. The built-in bias in these 
“excellence” schemes can thus lead to biases in resource allocation (Shibayama & Baba, 2015) In a sense, 
the narrative of “excellence”, both on a national or international level, supplants some of the discussion 
of research as a social need (Bozeman and Sarewitz, 2011). Furthermore, research funding is seen to 
favour projects which are deemed “innovative” or “ground-breaking”, rather than some of the more 
routine work associated with tackling disease (see Yaqub & Nightingale (2012) on the polio vaccine). 
According to one participant: 
For me, the operational research is much more what translates into how to manage the 
disease, how to translate it into policies. What I see is that research institutions and most 
of the research funding goes into much more this more fundamental research, looking at 
the virus, looking at the production of the vaccine. There's not much funding looking more 
to the operational side. (senior scientist and advisor at an international organization) 
More generally, interviewees saw funding mechanisms as being outside their sphere of influence, but as 
a determining factor for how research options are not only promoted, but also defined. At the very least, 
this points to a lack of transparency in terms of what types of projects are being funded, or potentially to 
a lack of engagement of stakeholders in setting priorities (Tallon, Chard, & Dieppe, 2000).  
Scholarly journals play a complex role in promoting, diffusing and, perhaps most importantly, rewarding 
various strands of avian influenza research. Many participants recognized that an a priori vision of the 
research landscape (such as the basis for the maps presented in Figures 6-10) are inherently skewed to 
reflect only research that is published in scholarly journals, thus excluding grey literature as well as 
correspondence or scientific advice to government that may or may not be made public. Pressure to 
publish is also perceived to have more subtle effects in terms of the priorities of researchers. 
You have certain articles that have been published, but the translation [to application or 
policy] of that is missing. Or for example, one of my big criticisms to many research 
projects, they go to villages. They do research in remote areas. But never this information 
is fed back to the villages themselves. You know? They are kind of so fixed to get it 
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published, but the community where the research was done never has any benefits of that 
research. 
Both science policy scholars and researchers indicated—albeit in different terms—that journals 
contribute to shape the overall balance of power between disciplines and among different specialties 
within the same discipline. In many cases these biases in power “distort” the research enterprise, pushing 
it towards certain areas (van Eck, Waltman, van Raan, Klautz, & Peul, 2013; Young, Ioannidis, & Al-Ubaydli, 
2008). For example, standards on sample sizes and statistical tests have a significant impact on fields such 
as epidemiology, defining what can be published and where. Additionally, the waxing and waning in 
popularity of different techniques for developing vaccines (e.g., the use of adjuvants), particularly where 
there are high-profile successes or failures reported (Miller et al., 2013; Reed, Bertholet, Coler, & Friede, 
2009; Shoenfeld & Agmon-Levin, 2011), can have a very fast and significant impact on what can and 
cannot be published in journals seen as prestigious.  
Most importantly, this perceived “distortion” is related to the journal hierarchy in science. Those closely 
connected to research recounted specific examples of certain scientific practices being more recognized 
than others.  For example, Figure 9 below shows the epistemic areas where so-called “high-impact” 
journals (Nature, Science, PNAS, Cell, BMJ and The Lancet) publish most: the figure clearly shows that 
these publications fall mainly in the biomedical areas – and underrepresent field studies and 
epidemiology, among others. Indeed, the ability of an article to receive high numbers of citations is larger 
in certain fields than in others (e.g., comparing biomedicine with social science). For example, according 
to one researcher:  
Well, it's certainly something published new in a high impact journal, like you see some of 
them here that are considered high impact. So, something appealing there on influenza, 
yeah, you would immediately have people that try to mimic - to repeat it or to maybe twist 
the research line in that direction. 
The case of perceived risks from dual-use research illustrates the various levels on which publishing 
pressures can operate. In this case, participants cited both a positive and negative impact of the 
controversy over dual-use research on publishing results from these lines of research (Edwards, Revill & 
Bezuidenhout, 2014). While existing or potential publishing restrictions may have discouraged some 
researchers from pursuing these lines of research, the visibility (as measured both by citations and other 
metrics such as tweets) received by those studies may also have made them attractive to top journals. 
Overall, most participants suggest that academic incentive structures may have the most significant 
impact on fostering a perceived mismatch between avian influenza research and desired outcomes. 
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Figure 9: Publication density map of the avian influenza research landscape (2004-2013), showing which terms occur most 
often (in red). Top: the same original "basemap" of Figure 6 (without the coloured clusters, using instead a density 
visualization) showing where the bulk of publications lie. Bottom: the map corresponding only to terms found in highest-
impact journals (specifically, we have chosen Nature, Lancet, Science, British Medical Journal, Cell and the Proceedings of the 
National Academy of Sciences of the USA).  Comparing the two, we see that “high-impact” publications tend to more heavily 
concentrated around basic virology research (bottom left) and much less around epidemiology and public health. 
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4.3.3 Missions of governmental organizations 
Avian influenza research takes place in a variety of settings associated with the different approaches 
(statistical analysis and modelling, “wet” laboratories, veterinary fieldwork, etc.), as well organizational 
contexts (government, private sector, non-governmental organization, or university). Naturally, scientific 
priorities vary among performing and funding institutions with different organizational missions, be they 
focused on regulation, communicating risk, informing national policy, informing clinical practice or 
producing “excellent” science, for instance, as in the case of many universities. We found that participants 
were often able to speak to “organizational pressures” on research in a general manner and, more 
importantly, relate their own organizational context to their roles as performers, funders or users of avian 
influenza research. Many participants pitted organizational pressures against stronger ones related to 
publishing or academic funding. For example, according to a scientist at a national health agency: 
Yes, more funding [for this type of research is needed] because these are routine 
surveillance activities. These are not research. It's different because I need more money to 
have people working in routine surveillance activity in order to let me work on the research 
activity, publications. 
Through our interviews, we identified three main organizational thrusts: policy development (namely, 
national or international regulation, prevention or coordination endeavours), knowledge production 
(often described as “pure” research) and clinical applications. These can be associated with government, 
universities (and similar “pure” research organizations), and hospitals (and other health-oriented 
institutions). Many organizations, particularly those associated with government or hospital settings, have 
other dominant priorities, thus research as an activity in itself might not be the main focus. The research 
they do perform tends to be targeted to specific clinical or policy-oriented applications, as illustrated in 
Figure 10. On the other hand, university researchers dominate the overall landscape (e.g., Figure 6) and 
select topics based on strategies to maximize funding (Laudel, 2006). Many stakeholders felt that the 
mandates of these governmental organizations were more connected to concrete risk mitigation 
strategies and thus, in some cases, helped shape the agenda of research according to specific societal 
outcomes.  
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Figure 10. Similar to Figure 9, density maps of overlays of a subset of research performed in hospital settings (top) and 
government settings (bottom). The articles for hospital settings were selected by isolating authors' abbreviated addresses (in 
Web of Science format) containing the strings “hosp” or “clin” (for hospitals), and “minist”, “natl” or “agcy” (for government). 
Those containing elements of both sets, or containing the string “univ” were excluded. 
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However, many participants also indicated that the disproportionate influence of international 
organizations such as the WHO in driving both control policies and research policies meant that there was 
less diversity in research and too much focus on human health, for example (as opposed to animals or 
livelihoods). This has already been documented in terms of the dominant role of the WHO at the centre 
not only of international response narratives, but also research priorities (Scoones, 2010, Chapter 1). 
Some view this as governance issues or questions of “organizational culture” which can be more or less 
serious and sometimes related to the indirect influence of the private sector. For example: 
[Fundamental virology researchers] have very good - historically very good connections with 
the public health authorities through the WHO; and also with - because the WHO meets every 
- two times a year to decide on the vaccine - vaccine composition. So, that means meeting 
scientists and the companies, so there is kind of - there's not a conflict of interest, but there is 
mutual interest to - to listen to each other's arguments. [...] Now WHO is very open about this 
because this is always published, what is then talked about. (senior university researcher) 
Other stakeholders highlighted the fact that different organizational missions hinder collaboration and 
sharing of information, which is central to tackling avian influenza as a global “grand challenge”. For 
example, people working in hospitals or in the field are sometimes less interested in collecting high-quality 
samples that can then be used in a laboratory setting. Similarly, those working for national governments 
may be reluctant to share information or even virus samples. This can be because data at a national level 
can point to deficiencies in preparedness and prevention, or because there is concern over their access or 
ability to use downstream outputs, such as vaccine use or production in the case in Indonesia (Fidler, 
2010). Overall, however, major organizational pressures are not viewed as accentuating the perceived 
divide  between research and societal needs, possibly because their missions are often explicitly stated as 
addressing societal needs. Nevertheless, the concentration of political or technocratic power in these 
organisations can be problematic as it may reduce diversity both in control/policy measures and in 
research.  
 
5. Discussion and conclusion 
This paper has presented an empirical investigation on priority setting in influenza research. Starting from 
the context of a contested and controversial research enterprise, we first explored the dominant 
narratives of avian flu. These are related both to strategies for the mitigation of a future global pandemic 
and to the existing research landscape as a set of “options” that help inform mitigation strategies. We 
found that different experts (policymakers, virologists, epidemiologists, etc.) have different perspectives 
on what should be done. We have observed a generalized difficulty of relating research agendas (science 
supply) with outcomes relevant for tacking influenza (societal demands). We have then concentrated our 
efforts on understanding what drives the research agenda and sets research priorities. To do so, we 
focused on the institutional pressures reported by a range of stakeholders and researchers.  
Our mixed-method (quantitative and qualitative) analysis has provided insights into the dynamics of 
research “supply” and “demand”, that have defined the rapid growth in avian influenza research over the 
last decade. In particular, we have discussed various ways in which influenza is framed as a mitigation of 
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the risk of a global pandemic, based on a range of social and technological interventions. We have also 
revealed how research options can be explored in distinct ways, as choices among dominant disciplines 
or between lab and fieldwork, for example. Human, as opposed to animal research is often seen as being 
at the forefront, just as research geared towards rapid technological advances supersedes incremental, 
often local, improvements to surveillance and detection. “Ground-breaking” laboratory work or large-
scale models of pandemic spread are often perceived to dominate the research landscape at the expense 
of “descriptive” field studies and publically-funded clinical trials. We can also cite other issues specific to 
avian influenza, such as the movement of birds across national boundaries, or the modes of coexistence 
of humans and birds as livestock within certain communities, which would require a more holistic 
approach to mitigating the risk of a pandemic. While we found clearly-defined “camps” between 
epidemiologists and virologists or between policymakers and scientists, for example, none of these 
divisions explained the diversity of views on what the priorities are – suggesting that personal, value-laden 
views play an important role. 
The interviews and the bibliometric analysis shed light on how public avian influenza research is currently 
being driven by private sector investment (e.g., towards the development of vaccines and antivirals), by 
“excellence”-oriented academic drivers (e.g., broadly towards basic biomedical research) and the 
mandates of large national and international organizations (especially those focused on human health). 
All three of these institutions have been found to explicitly and implicitly define what researchers choose 
to focus on to advance their work within their organization or within the scientific community.  
While some polarization of views of the positive or negative influence of the private sector is nothing 
surprising, a more notable result is the degree to which public—especially “academic”—research 
institutions (or “intra-scientific factors”) appear to foster a disconnect between research and outcomes 
(Luukkonen and Thomas, 2015). This represents a potential “relevance gap” in the research agenda 
(Nightingale & Scott, 2007). Our analysis points to systematic biases in the way public sector research is 
managed. These biases reinforce existing research options and the pursuit of an unsituated or 
decontextualized notion of “excellence” (Figure 9). Universities, as dominant institutions in the research 
landscape are more driven by a pursuit of “excellence”, the key to increased funding, among other 
rewards. Such an approach is neither neutral nor attentive of the diverse concerns of stakeholders. 
Governmental institutes and hospitals tend to drive research according to more demand-defined 
objectives (Figure 10).   
This study may have broader relevance for managing research in terms of “grand societal challenges” or 
for how science policy responds to “shocks” with a rapid influx of research resources. It suggests that for 
a given issue, a first step in priority setting is to acknowledge the existence of a broad range of possible 
relevant outcomes and many possible research options for achieving them. One can conceive of research 
portfolio management informed by diverging worldviews. The management should not rely only on pre-
existing research categories or “labels”, but rather map new research options and diverse potential 
outcomes. Most importantly, in addition to resource allocation decisions, designs for governance of 
research should explicitly take into account the institutional pressures in place that shape research 
agendas and their uptake.  
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